Y-mAbs Therapeutics - YMAB Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $16.57
Forecasted Upside: 9.53%
Number of Analysts: 6
Breakdown:
2 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$15.13 As of 04/19/2024 01:00 AM ET

▲ +0.13 (0.87%)

1 month | 3 months | 12 months

Get New Y-mAbs Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for YMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for YMAB

^$16.57

▲ +9.53% Upside Potential

This price target is based on 6 analysts offering 12 month price targets for Y-mAbs Therapeutics in the last 3 months. The average price target is $16.57, with a high forecast of $26.00 and a low forecast of $5.00. The average price target represents a 9.53% upside from the last price of $15.13.

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Y-mAbs Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

10/27/2022

0 strong buy ratings
4 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

1/25/2023

0 strong buy ratings
4 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

4/25/2023

0 strong buy ratings
4 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

7/24/2023

0 strong buy ratings
4 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

10/22/2023

0 strong buy ratings
4 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

1/20/2024

0 strong buy ratings
4 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

3/20/2024

0 strong buy ratings
4 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

4/19/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/6/2024	HC Wainwright	Boost Target	Buy ➝ Buy	$21.00 ➝ $22.00	Low
3/4/2024	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$22.00 ➝ $26.00	Low
3/4/2024	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$16.00 ➝ $26.00	Low
2/20/2024	HC Wainwright	Boost Target	Buy ➝ Buy	$11.00 ➝ $21.00	Low
2/12/2024	Wedbush	Reiterated Rating	Outperform	$12.00 ➝ $18.00	Low
11/15/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$11.00	Low
11/14/2023	Wedbush	Reiterated Rating	Outperform	$12.00	Low
8/22/2023	JPMorgan Chase & Co.	Lower Target	Underweight ➝ Underweight	$8.00 ➝ $7.00	Low
8/14/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$11.00	Low
8/14/2023	Morgan Stanley	Lower Target	Underweight ➝ Underweight	$7.00 ➝ $5.00	Low
7/25/2023	Canaccord Genuity Group	Boost Target	Buy	$21.00 ➝ $22.00	Low
5/15/2023	Bank of America	Boost Target		$6.00 ➝ $12.00	Low
5/10/2023	Wedbush	Upgrade	Neutral ➝ Outperform	$5.00 ➝ $13.00	N/A
4/4/2023	HC Wainwright	Lower Target	Buy	$19.00 ➝ $11.00	Low
4/3/2023	Guggenheim	Downgrade	Buy ➝ Neutral		Low
3/31/2023	Canaccord Genuity Group	Lower Target	Buy	$20.00 ➝ $18.00	Low
1/30/2023	BMO Capital Markets	Boost Target	Outperform	$12.00 ➝ $13.00	Low
1/27/2023	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$4.00	Low
1/5/2023	Cowen	Downgrade	Outperform ➝ Market Perform		Low
1/5/2023	Cowen	Downgrade	Outperform ➝ Market Perform		Low
12/5/2022	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$23.00 ➝ $27.00	Low
12/2/2022	Bank of America	Downgrade	Buy ➝ Neutral	$23.00 ➝ $5.00	Low
11/1/2022	BMO Capital Markets	Lower Target	Outperform	$29.00 ➝ $12.00	Low
10/31/2022	Canaccord Genuity Group	Lower Target		$35.00 ➝ $27.00	Low
10/31/2022	Kempen & Co	Downgrade	Buy ➝ Neutral		Low
10/31/2022	Morgan Stanley	Lower Target	Equal Weight	$17.00 ➝ $8.00	Low
10/31/2022	Guggenheim	Lower Target		$26.00 ➝ $18.00	Low
10/31/2022	Wedbush	Downgrade	Outperform ➝ Neutral	$21.00 ➝ $6.00	Low
10/31/2022	HC Wainwright	Lower Target	Buy	$63.00 ➝ $19.00	Low
10/31/2022	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$16.00 ➝ $7.00	Low
9/9/2022	Morgan Stanley	Boost Target	Equal Weight	$15.00 ➝ $17.00	Low
6/23/2022	BMO Capital Markets	Initiated Coverage	Outperform	$27.00	Low
5/10/2022	Wedbush	Lower Target	Outperform	$28.00 ➝ $21.00	High
4/29/2022	HC Wainwright	Reiterated Rating	Buy	$63.00	High
4/28/2022	Wedbush	Lower Target		$36.00 ➝ $28.00	High
2/28/2022	HC Wainwright	Lower Target	Buy	$68.00 ➝ $63.00	High
2/3/2022	Guggenheim	Initiated Coverage	Buy	$22.00	Medium
1/3/2022	JPMorgan Chase & Co.	Lower Target	Neutral	$30.00 ➝ $27.00	High
12/22/2021	HC Wainwright	Reiterated Rating	Buy	$68.00	Medium
11/19/2021	Morgan Stanley	Initiated Coverage	Equal Weight	$25.00	Medium
11/16/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$57.00 ➝ $30.00	High
10/8/2021	HC Wainwright	Reiterated Rating	Buy	$68.00	Low
9/14/2021	HC Wainwright	Reiterated Rating	Buy	$68.00	Medium
8/9/2021	HC Wainwright	Reiterated Rating	Buy	$68.00	Medium
7/7/2021	HC Wainwright	Reiterated Rating	Buy	$68.00	High
6/28/2021	HC Wainwright	Lower Target	Buy	$70.00 ➝ $68.00	Low
5/7/2021	Bank of America	Upgrade	Neutral ➝ Buy		High
4/21/2021	Wedbush	Lower Target	Outperform	$67.00 ➝ $52.00	High
3/22/2021	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$52.00	Low
3/1/2021	HC Wainwright	Boost Target	Buy	$65.00 ➝ $70.00	Low
1/15/2021	Bank of America	Downgrade	Buy ➝ Neutral	$56.00	High
12/17/2020	Wedbush	Boost Target	Outperform	$52.00 ➝ $71.00	High
12/17/2020	Barclays	Boost Target	Overweight	$55.00 ➝ $65.00	High
11/12/2020	Morgan Stanley	Boost Target	Equal Weight	$42.00 ➝ $45.00	Medium
11/9/2020	Barclays	Boost Target	Positive ➝ Overweight	$47.00 ➝ $53.00	Medium
11/9/2020	HC Wainwright	Boost Target	Buy	$52.00 ➝ $65.00	Medium
7/15/2020	Morgan Stanley	Boost Target	Equal Weight	$39.00 ➝ $42.00	High
7/1/2020	HC Wainwright	Reiterated Rating	Buy	$52.00	Low
5/11/2020	Wedbush	Boost Target	Outperform	$41.00 ➝ $48.00	Medium
5/11/2020	HC Wainwright	Boost Target	Buy	$41.00 ➝ $52.00	Medium
5/4/2020	Barclays	Initiated Coverage	Overweight	$44.00	Low
5/1/2020	Janney Montgomery Scott	Initiated Coverage	Buy		High
4/29/2020	Morgan Stanley	Initiated Coverage	Equal Weight		High
3/12/2020	Cowen	Reiterated Rating	Buy		High
1/28/2020	HC Wainwright	Reiterated Rating	Buy	$40.00 ➝ $41.00	Medium
12/24/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$39.00 ➝ $39.00	Medium
12/12/2019	Cowen	Initiated Coverage	Buy		Low
12/12/2019	HC Wainwright	Reiterated Rating	Buy	$40.00	Medium
12/2/2019	HC Wainwright	Reiterated Rating	Buy	$40.00	High
11/27/2019	Guggenheim	Initiated Coverage	Buy	$40.00	Low
11/19/2019	Guggenheim	Initiated Coverage	Buy	$40.00	High
11/18/2019	HC Wainwright	Reiterated Rating	Buy	$40.00	Low
11/4/2019	HC Wainwright	Reiterated Rating	Buy		Low
10/29/2019	HC Wainwright	Boost Target	Buy	$43.00	Low
10/28/2019	Cowen	Reiterated Rating	Buy		Low
9/3/2019	Wedbush	Initiated Coverage	Outperform	$38.00	Medium
8/26/2019	HC Wainwright	Set Target	Buy	$40.00	Low
7/1/2019	Cowen	Reiterated Rating	Buy		Low
6/10/2019	HC Wainwright	Reiterated Rating	Buy	$36.00 ➝ $40.00	High
5/28/2019	HC Wainwright	Set Target	Buy	$36.00	High

(Data available from 4/20/2019 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
3 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/22/2023

3 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/22/2023

5 very positive mentions
6 positive mentions
0 negative mentions
2 very negative mentions

Mentions as of

11/21/2023

1 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/21/2023

0 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

3 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/19/2024

10 very positive mentions
19 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/20/2024

2 very positive mentions
8 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Today's Range

Now: $15.13

$14.71

$15.41

50 Day Range

MA: $15.77

$13.76

$18.69

52 Week Range

Now: $15.13

$4.60

$20.90

Volume

467,186 shs

Average Volume

311,360 shs

Market Capitalization

$662.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Y-mAbs Therapeutics?: The following Wall Street sell-side analysts have issued stock ratings on Y-mAbs Therapeutics in the last twelve months: Bank of America Co., BMO Capital Markets, Canaccord Genuity Group Inc., HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, and Wedbush.
View the latest analyst ratings for YMAB.
What is the current price target for Y-mAbs Therapeutics?: 7 Wall Street analysts have set twelve-month price targets for Y-mAbs Therapeutics in the last year. Their average twelve-month price target is $16.57, suggesting a possible upside of 9.5%. BMO Capital Markets has the highest price target set, predicting YMAB will reach $26.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $5.00 for Y-mAbs Therapeutics in the next year.
View the latest price targets for YMAB.
What is the current consensus analyst rating for Y-mAbs Therapeutics?: Y-mAbs Therapeutics currently has 2 sell ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in YMAB, but not buy more shares or sell existing shares.
View the latest ratings for YMAB.
What other companies compete with Y-mAbs Therapeutics?: Other companies that are similar to Y-mAbs Therapeutics include Bicycle Therapeutics, Aerovate Therapeutics, Longboard Pharmaceuticals, Pharming Group and PureTech Health. Learn More about companies similar to Y-mAbs Therapeutics.
How do I contact Y-mAbs Therapeutics' investor relations team?: Y-mAbs Therapeutics' physical mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company's listed phone number is (646) 885-8505 and its investor relations email address is [email protected]. The official website for Y-mAbs Therapeutics is www.ymabs.com. Learn More about contacing Y-mAbs Therapeutics investor relations.

Y-mAbs Therapeutics - YMAB Stock Price Target and Predictions

Analyst Price Target for YMAB

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.16 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Y-mAbs Therapeutics?

What is the current price target for Y-mAbs Therapeutics?

What is the current consensus analyst rating for Y-mAbs Therapeutics?

What other companies compete with Y-mAbs Therapeutics?

How do I contact Y-mAbs Therapeutics' investor relations team?